Literature DB >> 11462198

Tularemia epidemic in northwestern Spain: clinical description and therapeutic response.

J L Pérez-Castrillón1, P Bachiller-Luque, M Martín-Luquero, F J Mena-Martín, V Herreros.   

Abstract

This study describes the clinical characteristics of tularemia in Spain's first epidemic outbreak and the therapeutic response and compares the efficacy of 3 antibiotics (streptomycin, ciprofloxacin, and doxycycline). For 142 cases of tularemia, the therapeutic failure rate was 22.5%; ciprofloxacin was the antibiotic with the lowest percentage of therapeutic failures and with the fewest side effects.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11462198     DOI： 10.1086/322601

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  53 in total

1.  Tularemia after a dormouse bite in Switzerland.

Authors:  A Friedl; I Heinzer; H Fankhauser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-05       Impact factor: 3.267

2.  AR-13, a Celecoxib Derivative, Directly Kills Francisella In Vitro and Aids Clearance and Mouse Survival In Vivo.

Authors:  Ky V Hoang; Haley E Adcox; James R Fitch; David M Gordon; Heather M Curry; Larry S Schlesinger; Peter White; John S Gunn
Journal:  Front Microbiol       Date:  2017-09-11       Impact factor: 5.640

3.  Conservation considerations for a management measure: an integrated approach to hare rearing and release.

Authors:  Christos Sokos; Periklis Birtsas; Konstantinos G Papaspyropoulos; Alexios Giannakopoulos; Labrini V Athanasiou; Katerina Manolakou; Vassiliki Spyrou; Charalambos Billinis
Journal:  Environ Manage       Date:  2014-10-26       Impact factor: 3.266

4.  Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.

Authors:  Karleigh A Hamblin; Stuart J Armstrong; Kay B Barnes; Carwyn Davies; Jonathan P Wong; James D Blanchard; Sarah V Harding; Andrew J H Simpson; Helen S Atkins
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

5.  [Fever and lymphadenopathy. Report of 4 cases of tularemia].

Authors:  C Bloch; A Friedl; F Zucol; A Widmer; N Khanna
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

6.  Complete genome sequence of Francisella tularensis subspecies holarctica FTNF002-00.

Authors:  Ravi D Barabote; Gary Xie; Thomas S Brettin; Steven H Hinrichs; Paul D Fey; Justin J Jay; Jennifer L Engle; Shubhada D Godbole; Jyothi M Noronha; Richard H Scheuermann; Liwei W Zhou; Christine Lion; Michael P Dempsey
Journal:  PLoS One       Date:  2009-09-16       Impact factor: 3.240

7.  Investigating an airborne tularemia outbreak, Germany.

Authors:  Anja M Hauri; Iris Hofstetter; Erik Seibold; Philip Kaysser; Juergen Eckert; Heinrich Neubauer; Wolf D Splettstoesser
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

Review 8.  Tularemia presenting as tonsillopharyngitis and cervical lymphadenitis: a case report and review of the literature.

Authors:  Osman Kürşat Arikan; Can Koç; Onder Bozdoğan
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-01-10       Impact factor: 2.503

9.  Genomic deletion marking an emerging subclone of Francisella tularensis subsp. holarctica in France and the Iberian Peninsula.

Authors:  M P Dempsey; M Dobson; C Zhang; M Zhang; C Lion; C B Gutiérrez-Martín; P C Iwen; P D Fey; M E Olson; D Niemeyer; S Francesconi; R Crawford; M Stanley; J Rhodes; D M Wagner; A J Vogler; D Birdsell; P Keim; A Johansson; S H Hinrichs; A K Benson
Journal:  Appl Environ Microbiol       Date:  2007-09-21       Impact factor: 4.792

10.  A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.

Authors:  Charlotte A Hall; Helen C Flick-Smith; Sarah V Harding; Helen S Atkins; Richard W Titball
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.